Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review and meta-analysis

Timotius Ivan Hariyanto a, Cynthia Putri a, Jessie Arisa a, Rocksya Fransisca V. Situmeang b, Andree Kurniawan c, *

a Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman street, Karawaci, Tangerang, Indonesia 15811
b Memory clinic, Department of Neurology, Siloam Hospitals Lippo Village, Boulevard Jendral Sudirman street, Karawaci, Tangerang, Indonesia 15811
c Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman street, Karawaci, Tangerang, Indonesia 15811

ARTICLE INFO

Keywords:
Coronavirus disease 2019
Covid-19
Dementia
Memory disturbance
Neurologic disease

ABSTRACT

Background: The number of positive and death cases from coronavirus disease 2019 (COVID-19) is still increasing until now. One of the most prone individuals, even in normal situations is patients with dementia. Currently, no study provides clear evidence regarding the link between dementia and COVID-19. This study aims to analyze the relationship between dementia and poor outcomes of COVID-19 infection.

Materials and Methods: We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until October 25th, 2020. All articles published on COVID-19 and dementia were retrieved. The quality of the study was assessed using the Newcastle Ottawa Scale (NOS) tool for observational studies. Statistical analysis was done using Review Manager 5.4 software.

Results: A total of 24 studies with 46,391 dementia patients were included in this meta-analysis. This meta-analysis showed that dementia was associated with composite poor outcome [RR 2.67 (95% CI 2.06 – 3.47), \( p < 0.00001 \), \( I^2 = 99\% \), random-effect modeling] and its subgroup which comprised of risk of COVID-19 infection [RR 2.76 (95% CI 1.43 – 5.33), \( p = 0.003 \), \( I^2 = 99\% \), random-effect modeling], severe COVID-19 [RR 2.63 (95% CI 1.41 – 4.90), \( p = 0.002 \), \( I^2 = 89\% \), random-effect modeling], and mortality from COVID-19 infection [RR 2.62 (95% CI 2.04 – 3.36), \( p < 0.00001 \), \( I^2 = 96\% \), random-effect modeling].

Conclusions: Extra care and close monitoring should then be provided to patients with dementia to minimize the risk of infections, preventing the development of severe and mortality outcomes.

1. Introduction

World Health Organization (WHO) first declared coronavirus disease 2019 (COVID-19) as a pandemic in March 2020, and now, seven months after that, the number of positive and death cases are still increasing. This global pandemic has caused a significant impact on health, social, and economic aspects around the world. Thus, identification of the risk factors that contribute to the development of severe infections is important to enabling risk stratification, optimizing the hospital resources reallocation, and guiding public health recommendations and interventions. (T. I. Hariyanto & Kurniawan, 2020)

Several comorbidities have been demonstrated to be associated with severe COVID-19 outcomes such as hypertension, diabetes, dyslipidemia, anemia, cardiovascular disease, thyroid disease, and pulmonary disease. (T. I. Hariyanto & Kurniawan, 2020; Huang et al., 2020; Kwenandar et al., 2020)

During normal times, individuals with dementia are the most vulnerable persons as they depend on other people for their day to day survival. In a previous study, it has been shown that dementia increases the risk of morbidity and mortality among hospitalized patients, including the severity of the respiratory disease. (Liao et al., 2015)

Unfortunately, until now, no study provides clear evidence regarding the link between dementia and COVID-19. This article aims to explore the potential association between dementia and poor outcomes of COVID-19 infection.
2. Materials and methods

2.1. Eligibility criteria

Studies were included in this review if met the following inclusion criteria: representation for clinical questions (P: positive/confirmed cases of COVID-19; I: a group of patients with dementia as their comorbidity; C: a group of patients without dementia; O: composite poor outcomes which comprise of risk of COVID-19 infection, severe COVID-19, and mortality), type of study was a randomized control trial, cohort, clinical trial, case-cohort, and cross-over design, and if the full-text article was available. The following types of articles were excluded: articles other than original research (e.g., review articles, letters, or commentaries); case reports; articles not in the English language; articles on research in pediatric populations (17 years of age or younger); and articles on research in pregnant women.

2.2. Search strategy and study selection

A systematic search of the literature was conducted on PubMed and Europe PMC using the keywords “dementia” OR “major cognitive impairment” OR “clinical characteristics” OR “comorbidities” OR “risk factors” AND “coronavirus disease 2019” OR “COVID-19”, between 2019 and present time (October 25th, 2020) with language restricted to English only. The title, abstract, and full text of all articles identified that matched the search criteria were assessed, and those reporting the rate of dementia in COVID-19 patients with a clinically validated definition of “severe disease” and “mortality” were included in this meta-analysis. The references of all identified studies were also analyzed (forward and backward citation tracking) to identify other potentially eligible articles. The study was carried out per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. (Moher, Liberati, Tetzlaff & Altman, 2009)

2.3. Data extraction and quality assessment

Data extraction was performed independently by two authors, we used standardized forms that include author, year, study design, number of participants, age, gender, number of patients with dementia, and proportion of patients with each outcome of COVID-19.

The outcome of interest was the composite poor outcome that comprised of risk of COVID-19 infection, severe COVID-19, and mortality. The risk of COVID-19 infection was defined as the likelihood of someone getting contracted by COVID-19. Severe COVID-19 was defined as patients who had any of the following features at the time of, or after, admission: (1) respiratory distress (≥30 breaths per min); (2) oxygen saturation at rest ≤93%; (3) ratio of the partial pressure of arterial oxygen (PaO2) to a fractional concentration of oxygen inspired air (FiO2) ≤300 mmHg; or (4) critical complication (respiratory failure, septic shock, and or multiple organ dysfunction/failure) or admission into ICU. Mortality outcome from COVID-19 was defined as the number of patients who were dead because of COVID-19 infection.

Two investigators independently evaluated the quality of the included cohort and case-control studies using the Newcastle–Ottawa Scale (NOS). (Margulis et al., 2014) The selection, comparability, and exposure of each study were broadly assessed and studies were assigned a score from zero to nine. Studies with scores ≥7 were considered of good quality.

2.4. Statistical analysis

A meta-analysis was performed using Review Manager 5.4 (Cochrane Collaboration) software. Dichotomous variables were calculated using the Mantel-Haenszel formula with a random-effects model regardless of heterogeneity. The effect estimate was reported as risk ratio (RR) along with its 95% confidence intervals (CIs) for dichotomous variables, respectively. P-value was two-tailed, and the statistical significance was set at ≤0.05. Subgroup analysis was performed for each component of composite poor outcomes. We performed Begg’s funnel-plot analysis to qualitatively assess the risk of publication bias.

3. Results

3.1. Study selection and characteristics

A total of 10,260 records were obtained through systematic electronic searches. After the removal of duplicates, 5370 records remained. A total of 5332 records were excluded after screening the titles/abstracts because they did not match our inclusion and exclusion criteria. After evaluating 38 full-texts for eligibility, 6 full-text articles were excluded
because they do not have the control/comparison group, 5 full-text articles were excluded because they do not have the outcome of interest (risk of COVID-19 infection, severe COVID-19, and mortality), 3 full-text articles were excluded because the articles were not in English, and finally, 24 studies (Atkins et al., 2020; Bianchetti et al., 2020; Covino et al., 2020; Docherty et al., 2020; Giorgi Rossi et al., 2020; Harrison, Fazio-Eynullayeva, Lane, Underhill & Lip, 2020; Hong et al., 2020; Hwang, Kim, Park & Chang, 2020; Jang et al., 2020; Jang et al., 2020; Kabarriti et al., 2020; Knights et al., 2020; Miyashita et al., 2020; Poblador-Plou et al., 2020; Sapey et al., 2020; Sang et al., 2020; Sung et al., 2020; Yang et al., 2020) with a total of 4648,247 sample size and 46,391 dementia patients were included in the meta-analysis (Fig. 1). Of a total of 24 included studies, 21 were retrospective cohort, 2 studies were prospective cohort, while the remaining 1 study was a case-control study. The essential characteristics of the included studies are summarized in Table 1.

3.2. Quality of study assessment

Studies with various study designs including cohort and case-control were included in this review and assessed accordingly with the appropriate scale or tool. Newcastle Ottawa Scales (NOS) were used to assess the cohort and case-control studies (Table 2). All included studies were appropriate scale or tool. Newcastle Ottawa scales (NOS) were used to assess the appropriate scale or tool. Newcastle Ottawa Scales (NOS) were used to assess the appropriate scale or tool. Newcastle Ottawa Scales (NOS) were used to assess the appropriate scale or tool. Newcastle Ottawa Scales (NOS) were used to assess the appropriate scale or tool. Newcastle Ottawa Scales (NOS) were used to assess the appropriate scale or tool. Newcastle Ottawa Scales (NOS) were used to assess the appropriate scale or tool. Newcastle Ottawa Scales (NOS) were used to assess the appropriate scale or tool. Newcastle Ottawa Scales (NOS) were used to assess the appropriate scale or tool. Newcastle Ottawa Scales (NOS) were used to assess the appropriate scale or tool.

| Study | Sample size | Design | Outcome | Age (years) | Dementia patients n (%) | Non-dementia patients n (%) |
|-------|-------------|--------|---------|-------------|------------------------|-----------------------------|
| Atkins et al. (2020) | 269,070 | Retrospective cohort | Risk of infection | 73.1 ± 4.4 | 888 (0.3%) | 268,182 (99.7%) |
| Bianchetti et al. (2020) | 627 | Retrospective cohort | Mortality | 70.7 ± 12.9 | 82 (13.1%) | 545 (86.9%) |
| Covino et al. (2020) | 69 | Retrospective cohort | Mortality | 85 ± 5.1 | 8 (11.6%) | 61 (88.4%) |
| Docherty et al. (2020) | 20,133 | Prospective cohort | Mortality | 70.9 ± 17.7 | 2360 (13.5%) | 15,099 (86.5%) |
| Giorgi Rossi et al. (2020) | 2653 | Prospective cohort | Mortality | 54.7 ± 18.3 | 107 (4%) | 2546 (96%) |
| Harrison et al. (2020) | 31,461 | Retrospective cohort | Mortality | 49.3 ± 20.7 | 1031 (3.2%) | 30,430 (96.7%) |
| Hong et al. (2020) | 98 | Retrospective cohort | Mortality | 55.4 ± 17.1 | 3 (3.1%) | 95 (96.9%) |
| Hwang et al. (2020) | 103 | Retrospective cohort | Mortality | 67.6 ± 15.3 | 11 (10.6%) | 92 (89.4%) |
| Jang et al. (2020) | 110 | Retrospective cohort | Mortality | 56.9 ± 17 | 4 (3.6%) | 106 (96.4%) |
| Ji et al. (2020) | 7341 | Case-control | Mortality | 47 ± 19 | 368 (5%) | 6973 (95%) |
| Kabarriti et al. (2020) | 5902 | Retrospective cohort | Mortality | 48.3 ± 20.4 | 303 (5.1%) | 5599 (94.9%) |
| Knights et al. (2020) | 108 | Retrospective cohort | Mortality | 68.7 ± 1.5 | 16 (15%) | 92 (85%) |
| Kokoszka-Bargiel et al. (2020) | 53 | Retrospective cohort | Mortality | 62.4 ± 10.4 | 12 (22.6%) | 41 (77.4%) |
| Lee et al. (2020) | 694 | Retrospective cohort | Mortality | 52.1 ± 18.2 | 10 (1.4%) | 684 (98.6%) |
| Miyashita et al. (2020) | 2071 | Retrospective cohort | Mortality | 68.5 ± 12.7 | 98 (4.7%) | 1973 (95.3%) |
| Mohamed et al. (2020) | 144,297 | Retrospective cohort | Mortality | 75.8 ± 12.5 | 23,961 (16.6%) | 120,336 (83.4%) |
| Moon et al. (2020) | 352 | Retrospective cohort | Mortality | 55.6 ± 25.1 | 35 (9.9%) | 317 (90.1%) |
| Nystad et al. (2020) | 4118,831 | Retrospective cohort | Mortality | 53.8 ± 15.1 | 15,190 (9.4%) | 41,036,641 (99.6%) |
| Poblador-Plou et al. (2020) | 4412 | Retrospective cohort | Mortality | 63.3 ± 18.1 | 468 (10.6%) | 3944 (89.4%) |
| Rozendel et al. (2020) | 34,503 | Retrospective cohort | Mortality | 61.5 ± 13.4 | 1039 (23%) | 33,464 (97%) |
| Sapey et al. (2020) | 2217 | Retrospective cohort | Mortality | 71.6 ± 19.2 | 326 (14.7%) | 1891 (85.3%) |
| Sung et al. (2020) | 3060 | Retrospective cohort | Mortality | 42 ± 22.9 | 65 (2.5%) | 2621 (97.5%) |
| Wan et al. (2020) | 30 | Retrospective cohort | Mortality | 64.2 ± 14.7 | 5 (16.6%) | 25 (83.4%) |
| Yang et al. (2020) | 52 | Retrospective cohort | Mortality | 59.7 ± 13.3 | 1 (1.9%) | 51 (98.1%) |

Table 2
Newcastle-Ottawa quality assessment of observational studies.

| First author, year | Study design | Selection | Comparability | Outcome | Total score | Result |
|-------------------|--------------|-----------|---------------|---------|-------------|--------|
| Atkins et al. (2020) | Cohort | *** | ** | *** | 8 | Good |
| Bianchetti et al. (2020) | Cohort | ** | ** | *** | 7 | Good |
| Covino et al. (2020) | Cohort | *** | ** | *** | 8 | Good |
| Docherty et al. (2020) | Cohort | *** | ** | *** | 9 | Good |
| Giorgi Rossi et al. (2020) | Cohort | *** | ** | *** | 8 | Good |
| Harrison et al. (2020) | Cohort | *** | ** | *** | 8 | Good |
| Hong et al. (2020) | Cohort | ** | ** | *** | 7 | Good |
| Jang et al. (2020) | Cohort | ** | ** | *** | 8 | Good |
| Poblador-Plou et al. (2020) | Case-control | *** | ** | *** | 8 | Good |
| Kabarriti et al. (2020) | Cohort | *** | ** | *** | 8 | Good |
| Knights et al. (2020) | Cohort | ** | ** | *** | 7 | Good |
| Kokoszka-Bargiel et al. (2020) | Cohort | *** | ** | *** | 8 | Good |
| Lee et al. (2020) | Cohort | ** | ** | *** | 7 | Good |
| Miyashita et al. (2020) | Cohort | ** | ** | *** | 7 | Good |
| Mohamed et al. (2020) | Cohort | ** | ** | *** | 7 | Good |
| Moon et al. (2020) | Cohort | ** | ** | *** | 7 | Good |
| Nystad et al. (2020) | Cohort | *** | ** | *** | 8 | Good |
| Poblador-Plou et al. (2020) | Cohort | *** | ** | *** | 8 | Good |
| Rozendel et al. (2020) | Cohort | *** | ** | *** | 8 | Good |
| Sapey et al. (2020) | Cohort | **** | ** | *** | 9 | Good |
| Sung et al. (2020) | Cohort | ** | ** | *** | 8 | Good |
| Wang et al. (2020) | Cohort | ** | ** | *** | 8 | Good |
| Yang et al. (2020) | Cohort | ** | ** | *** | 8 | Good |
3.3. Dementia and outcomes

Our pooled analysis showed that dementia was associated with composite poor outcome [RR 2.67 (95% CI 2.06 – 3.47), p < 0.00001, I² = 99%, random-effect modeling] (Fig. 2). Subgroup analysis showed that dementia was associated with higher risk of COVID-19 infection [RR 2.76 (95% CI 1.43 – 5.33), p = 0.003, I² = 99%, random-effect modeling], severe COVID-19 [RR 2.63 (95% CI 1.41 – 4.90), p = 0.002, I² = 89%, random-effect modeling], and mortality from COVID-19 infection [RR 2.62 (95% CI 2.04 – 3.36), p < 0.00001, I² = 96%, random-effect modeling].

3.4. Publication bias

The funnel-plot analysis showed a qualitatively symmetrical inverted funnel-plot for the association between dementia and composite poor outcome (Fig. 3), showing no indication of publication bias.
medical conditions that could increase the severity of infections. Older patients with COVID-19 infection tend to present with atypical symptoms. They may be afebrile with non-respiratory symptoms, such as delirium or isolated functional decline without any obvious physical symptoms. (D'Adamo, Yoshikawa & Ouslander, 2020) These atypical presentations of COVID-19 may impede the early recognition of the disease, increase COVID-19 spread, and mortality. Moreover, in a meta-analysis of 611,583 COVID-19 patients, age over 60 years was found to be a risk factor for disease progression. (Bonanad et al., 2020) This fact could be influenced by both the physiological aging process and, especially, the greater prevalence in older adult patients of frailty and comorbidities that contribute to a decrease in functional reserve that reduces intrinsic capacity and resilience and hinders the fight against infections. (Bonanad et al., 2020) Second, patients with dementia were associated with the ApoE ε4 genotype. (Kuo, Pilling, Atkins, Kuchel & Melzer, 2020) ApoE itself has lipoprotein function and modulates the macrophage pro/anti-inflammatory phenotypes (Tudorache, Trusca & Melzer, 2020) and is expressed by many cell types in the lung, including macrophages, type I and type II alveolar epithelial cells (Pilling, L., C., Kuo, C. L., & Kuchel, G. A. (2020). Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci, 75(11), 2224–2230. https://doi.org/10.1093/gerona/glaa183.) and is expressed by many cell types in the lung, making it a potential marker of COVID-19 in older adults and have been associated with worse outcomes in COVID-19. (Bonanad et al., 2020) Second, patients with dementia were associated with the ApoE ε4 genotype. (Kuo, Pilling, Atkins, Kuchel & Melzer, 2020) ApoE itself has lipoprotein function and modulates the macrophage pro/anti-inflammatory phenotypes (Tudorache, Trusca & Gafencu, 2017) and is expressed by many cell types in the lung, including macrophages, type I and type II alveolar epithelial cells (Gordon et al., 2019), therefore it is possible that having one or two copies of ApoE4 can increase the risk of having severe COVID-19 infection by robust innate immune response and cytokine storm that results in acute respiratory distress syndrome (ARDS). Third, inflammation also plays an important role in the pathogenesis of dementia. In addition to amyloid protein, inflammatory molecules, including acute inflammatory reactants and inflammatory cytokines, have been found in the cerebrospinal fluid of dementia patients. (Kinney et al., 2018; Simone & Tan, 2011) These persistent inflammatory state of dementia patients may be the cause of the increased peripheral blood white blood cells (WBC) and neutrophil counts in dementia patients with COVID-19. (Harrison et al., 2020) On the other side, a meta-analysis study has shown that a high level of leukocyte counts and the high neutrophil-lymphocyte ratio was associated with a higher risk of developing severe COVID-19 and mortality from COVID-19. (Elshazli et al., 2020) Finally, people with dementia, due to the nature of their cognitive decline, would require the care and support of carers such as dementia caregivers in order to be able to follow healthcare and preventive measures such as wearing face masks and washing their hands with water and soap or hand sanitizers. (Suzuki et al., 2020) However, during this COVID-19 pandemic, the availability of caregivers becomes limited which may cause dementia patients unable to follow healthcare and preventive measures therefore making them posed a higher risk of contracting an infection from COVID-19. (Dang et al., 2020).

The limitation of this study is that the presence of confounding factors such as patients’ age, other comorbid conditions, nutritional status, and daily medication that can affect the relationship between dementia and mortality from COVID-19 should still be considered. However, with this study, we hope that dementia can further be considered as an important factor and comorbidity in COVID-19 patients.

5. Conclusions and implications

Hence, patients with dementia should be given extra care and monitoring to minimize exposure to the virus. Physicians can use the telemedicine-based practice to provide care and evaluations for dementia patients to minimize their visit to the hospitals. Physicians and caregivers should also be engaged in close monitoring of dementia patients with suspected COVID-19, for early diagnosis and treatment to avoid severe infections. The hospitals can provide Special Care Geriatric COVID-19 units for dementia and elderly patients who contract with COVID-19, which is filled with a team of mental health professionals (doctors, nurses, and psychological counselors), to give better care, more strict monitoring, and enable the healthcare providers in that units to focus only on the management of dementia patients so that the morbidity and mortality from COVID-19 can be reduced. Finally, dementia should be regarded as an important factor in future risk stratification models for COVID-19.

Funding

None.

CRediT authorship contribution statement

Timotius Ivan Hariyanto: Conceptualization, Data curation, Methodology, Investigation, Validation, Visualization, Writing - original draft, Writing - review & editing. Cynthia Putri: Conceptualization, Data curation, Methodology, Investigation, Validation, Visualization, Writing - original draft, Writing - review & editing. Jessie Arisa: Conceptualization, Data curation, Methodology, Investigation, Validation, Visualization, Writing - original draft, Writing - review & editing. Rockies Fransisca V. Situmeang: Conceptualization, Visualization, Resources, Supervision, Writing - original draft, Writing - review & editing. Andree Kurniawan: Conceptualization, Visualization, Resources, Supervision, Writing - original draft, Writing - review & editing.

Declaration of Competing Interest

None.

Acknowledgement

References

Ariello, A., Farzaneh, F., Candore, G., Caruso, C., Davinelli, S., & Gambino, C. M. (2019). Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. Frontiers in immunology, 10, 2247. Sep 25 https://doi.org/10.3389/fimmu.2019.02247.

Ardini, J. L., Masoli, J. A. H., Belgado, J., Pilling, L. C., Kuo, C. L., & Kuchel, G. A. (2020). Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci, 75(11), 2224–2230. https://doi.org/10.1093/gerona/glaa183.

Bianchetti, A., Rezzini, R., Guerini, F., Boffelli, S., Ranieri, P., Minelli, G., et al. (2020). Clinical presentation of COVID-19 in dementia patients. The journal of nutrition, health & aging, 24(6), 560–562. https://doi.org/10.1007/s12603-020-1389-1.

Bonanad, C., García-Blas, S., Tarazona-Santabalbina, F., Sanchis, J., Bertomeu-González, V., Fíclla, L., et al. (2020). The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysist With 611,583 Subjects. Journal of the American Medical Directors Association, 21(7), 915–918. Jul https://doi.org/10.1016/j.jamda.2020.05.045.

Covino, M., Matteis, G. D., Santoro, M., Sabia, L., Simeoni, B., Candelli, M., et al. (2020). Clinical characteristics and prognostic factors in COVID-19 patients aged ≥80 years. Geriatrics & gerontology international, 1–5. https://doi.org/10.1111/jgs.13960.

D’Adamo, H., Yoshikawa, T., & Ouslander, J. (2020). Coronavirus disease 2019 in geriatrics and long-term care: The ARCDs of COVID-19. Journal of the American Geriatrics Society, 68(5), 912–917. https://doi.org/10.1111/jgs.16445.

Dang, S., Penney, L. S., Trivedi, R., Noel, P. H., Pugh, M. J., Finley, E., et al. (2020). Caring for Caregivers During COVID-19. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.16726. https://doi.org/10.1111/jgs.16726.

Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., et al. (2020). ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ (Clinical research ed.), 369, m1895. https://doi.org/10.1136/bmj.m1895.

Elshazli, R. M., Torah, E. A., Elgami, A., El-Mowafy, M., El-Mesery, M., & Amin, M. N. (2020). Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients. PloS one, 15(8), Article e0238160. https://doi.org/10.1371/journal.pone.0238160.

Giorgi Rossi, P., Martino, M., Formisano, D., Venturelli, F., Vicentini, M., Grilli, R., & Reggio Emilia COVID-19 Working Group. (2020). Characteristics and outcomes of a
